Research, regulatory, and clinical decision-making: the importance of scientific integrity.

• There have been growing concerns about the reliability and validity of the underlying research that supports regulatory and clinical decision-making

[1]  Nicholas C. Ide,et al.  Trial Registration at ClinicalTrials.gov between May and October 2005. , 2005, The New England journal of medicine.

[2]  Kristin L. Sainani,et al.  Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials , 2017, JAMA internal medicine.

[3]  D. Fanelli.  How Many Scientists Fabricate and Falsify Research? A Systematic Review and Meta-Analysis of Survey Data , 2009, PloS one.

[4]  Harlan M. Krumholz,et al.  Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010 , 2017, JAMA.

[5]  J. Rasko,et al.  Show drugs work before selling them , 2017, Nature.

[6]  H. Krumholz.  Documenting the methods history: would it improve the interpretability of studies? , 2012, Circulation. Cardiovascular quality and outcomes.

[7]  J. Ioannidis.  Why Most Published Research Findings Are False , 2019, CHANCE.

[8]  Harlan M. Krumholz,et al.  Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. , 2014, JAMA.

[9]  H. Krumholz,et al.  Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. , 2015, JAMA.

[10]  H. Bauchner,et al.  Sharing clinical trial data: a proposal from the International Committee of Medical Journal Editors , 2016, Canadian Medical Association Journal.

[11]  P. Gøtzsche,et al.  Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. , 1999, JAMA.

[12]  Tony Tse,et al.  The proposed rule for U.S. clinical trial registration and results submission. , 2015, The New England journal of medicine.

[13]  Josh Rising,et al.  The Food and Drug Administration's unique device identification system: better postmarket data on the safety and effectiveness of medical devices. , 2014, JAMA internal medicine.

[14]  M. Cabana,et al.  Why don't physicians follow clinical practice guidelines? A framework for improvement. , 1999, JAMA.

[15]  Francis S. Collins,et al.  Toward a New Era of Trust and Transparency in Clinical Trials. , 2016, JAMA.

[16]  M. Baker.  1,500 scientists lift the lid on reproducibility , 2016, Nature.

[17]  M. Drummond,et al.  Inclusion of cost effectiveness in licensing requirements of new drugs : The fourth hurdle , 2017 .

[18]  N. Desai,et al.  Medicare Formulary Changes After the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline. , 2017, Journal of the American College of Cardiology.

[19]  Daniel M Fox,et al.  Evidence of evidence-based health policy: the politics of systematic reviews in coverage decisions. , 2005, Health affairs.

[20]  G. Alexander,et al.  The Food and Drug Administration Amendments Act and postmarketing commitments. , 2013, JAMA.

[21]  J. Ross,et al.  US drug marketing: how does promotion correspond with health value? , 2017, British Medical Journal.

[22]  H. Krumholz,et al.  The New Era of Informed Consent: Getting to a Reasonable-Patient Standard Through Shared Decision Making. , 2016, JAMA.

[23]  Michael K Paasche-Orlow,et al.  Beyond Medication Reconciliation: The Correct Medication List , 2017, JAMA.

[24]  S. Timmermans,et al.  The Promises And Pitfalls Of Evidence-Based Medicine Nonadherence to practice guidelines remains the major barrier to the successful practice of evidence-based medicine. , 2005 .

[25]  H. Krumholz,et al.  Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review , 2017, British Medical Journal.

[26]  J. Ross,et al.  Association between FDA black box warnings and Medicare formulary coverage changes. , 2017, The American journal of managed care.

[27]  M. Drummond,et al.  Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  Nicholas C. Ide,et al.  The ClinicalTrials.gov results database--update and key issues. , 2011, The New England journal of medicine.

[29]  J. Knottnerus,et al.  Evidence-based medicine: achievements and prospects. , 2017, Journal of clinical epidemiology.

[30]  J. B. Layton,et al.  Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013 , 2017, JAMA.

[31]  John P. A. Ioannidis,et al.  How to Make More Published Research True , 2014, PLoS medicine.